KTOV - Kitov Pharma Ltd

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.5899
+0.1034 (+4.1585%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close2.4865
Open2.4800
Bid2.4000 x 1000
Ask2.5500 x 500
Day's Range2.4600 - 2.7400
52 Week Range1.2700 - 3.4400
Volume191,733
Avg. Volume154,175
Market Cap27.166M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-1.9000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • PR Newswire2 months ago

    Kitov Announces Consensi™ as Brand Name for KIT-302

    "The receipt of the FDA's permission to use Consensi as the brand name for our lead drug is another important step in executing on our corporate strategy and will facilitate the commercialization of KIT-302, once approved by the FDA, " stated J. Paul Waymack, M.D., Sc.D., Kitov's Chairman of the Board and Chief Medical Officer. Consensi™ is a combination drug that is intended to simultaneously treat pain caused by osteoarthritis, as well as hypertension, which is a common side effect of stand-alone drugs that treat osteoarthritis pain.   Consensi™ is comprised of two FDA approved drugs, celecoxib (Celebrex®), a COX-2 inhibitor, for the treatment of pain caused by osteoarthritis, and amlodipine besylate (Norvasc®), a calcium channel blocker for lowering blood pressure.

  • PR Newswire4 months ago

    Kitov Pharmaceuticals Announces Receipt of FDA's Favorable Response to NT219's pre-IND Meeting Package

    TASE: KTOV), an innovative biopharmaceutical company, announced today that it has received the U.S. Food and Drug Administration's (FDA) response to the NT219's pre-IND meeting package.  FDA has agreed to the proposed Chemistry Manufacturing and Controls (CMC), preclinical, and clinical development plans for NT219. For the clinical development plan, the FDA agreed with TyrNovo's proposed development plan to test NT219 in combination with gemcitabine for the treatment of advanced pancreatic cancer.

  • PR Newswire4 months ago

    Kitov Pharmaceuticals Announces Phase III/IV Clinical Trial for KIT-302 Successfully Meets Primary Endpoint, and also Demonstrates Drug Candidate Improves Renal Function

    TASE: KTOV), an innovative biopharmaceutical company, announced today that its randomized double-blind, placebo-controlled renal function clinical trial for its lead drug candidate, KIT-302, successfully met its primary efficacy endpoint. Data from the trial demonstrated that KIT-302 lowered systolic blood pressure a comparable amount to the widely used antihypertension drug, amlodipine besylate, thus meeting the trial's primary efficacy endpoint of achieving at least 50% of the amlodipine reduction (p=0.019).

  • PR Newswire5 months ago

    Kitov Boosts Ownership in TyrNovo and Oncology Platform Through Exchange of Shares for Stock

    - Kitov acquires an additional 27% ownership stake in TyrNovo and NT219, its oncology therapeutic candidate, in exchange for Kitov stock at a value of $2.50 per ADS. - NT219 is a first-in-class drug candidate presenting a new paradigm of cancer treatment - overcoming tumors' cancer drug resistance. TEL AVIV, Israel, Oct. 6, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), ("Kitov" or "the Company") an innovative biopharmaceutical company, announced today the acquisition of an additional 27% stake in TyrNovo Ltd., a privately- held developer of novel small molecules in the oncology therapeutic field, from unaffiliated minority shareholders.  As announced on January 13, 2017, Kitov had acquired a controlling interest, which is now approximately 65% of TyrNovo.  After the closing of this transaction, Kitov will hold approximately 92% of TyrNovo's issued and outstanding ordinary shares.

  • ACCESSWIRE5 months ago

    Corporate News Blog - US FDA Accepts Kitov Pharma’s Lead Drug Candidate for Full Review

    LONDON, UK / ACCESSWIRE / October 4, 2017 / Pro-Trader Daily looks at the latest corporate events and news making the headlines for Kitov Pharmaceuticals Holdings Ltd (NASDAQ: KTOV ), following which we ...

  • PR Newswire5 months ago

    Kitov Announces Filing by FDA of New Drug Application for KIT-302

    Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) filed the Company's New Drug Application (NDA) for KIT-302, its lead drug candidate, thereby accepting the NDA for a full review. KIT-302 is a patented combination of celecoxib and amlodipine, and is intended to treat osteoarthritis pain and hypertension simultaneously.

  • PR Newswire6 months ago

    Kitov Pharmaceuticals Provides Corporate Update and Reports First Half 2017 Financial Results

    TEL AVIV, Israel , Aug. 16, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) (TASE: KTOV), an innovative biopharmaceutical company, today provided a corporate update and reported ...

  • PR Newswire7 months ago

    Kitov Submits New Drug Application to FDA for KIT-302

    Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for KIT-302, its lead drug candidate. KIT-302 is a patented combination of celecoxib and amlodipine, and is intended to treat osteoarthritis pain and hypertension simultaneously. The company expects that within 60 days the FDA will determine whether the NDA is complete and acceptable for filing.

  • PR Newswire7 months ago

    Kitov Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda® in Immune-Oncology Preclinical Model

    TEL AVIV, Israel, July 18, 2017 /PRNewswire/ -- Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV) (KTOV), an innovative biopharmaceutical company, today announced  results of a pre-clinical study demonstrating that NT-219, the lead drug candidate of its subsidiary TyrNovo Ltd., in combination with Keytruda®, converted non-responding tumors to responders and blocked tumor progression in an immune-oncology preclinical model. The study, conducted in collaboration with researchers at Bar Ilan University and Rabin Medical Center, assessed NT-219's ability to overcome cancer drug resistance in a patient-derived xenograft (PDX) model of immune-deficient mice, in which a tumor originated from an esophagus cancer biopsy was implanted.

  • PR Newswire7 months ago

    Kitov Pharmaceuticals Announces Pricing of $3.5 Million Registered Direct Offering

    Kitov Pharmaceuticals (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company focused on late-stage drug development, today announced that it has entered into definitive agreements with institutional and other investors providing for the issuance of 2,431,746 American Depositary Shares (ADS) at a purchase price of $1.45 per ADS in a registered direct offering. Kitov will issue unregistered warrants to purchase up to 1,215,873 ADSs. The ADSs described above were offered pursuant to a shelf registration statement on Form F-3 (File No. 333-215037), which was declared effective by the United States Securities and Exchange Commission  (the "SEC") on December 14, 2016.

  • Benzinga8 months ago

    Kitov Pharmaceuticals Says on July 6 Named Gil Ben-Menachem to Fill Vacancy on Board

     Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV ) is announcing that on July 6, 2017 the Board of Directors (the “Board”) of the Company determined to fill a vacancy on the Board, and to appoint Gil ...

  • PR Newswire8 months ago

    Kitov Updates on KIT-302 New Drug Application

    Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, announced today that it has begun the process of digitizing its New Drug Application (NDA) for KIT-302, its lead drug candidate, through Parexel International Corporation, a clinical research organization, which has been engaged by Kitov for the preparation of the NDA into the standard, accepted electronic format of the U.S. Food and Drug Administration (FDA). KIT-302 is Kitov's patented combination of celecoxib and amlodipine, is intended to treat osteoarthritis pain and hypertension simultaneously.

  • PR Newswire8 months ago

    TyrNovo Ltd. to Participate in 2017 BIO International Convention

    TyrNovo Ltd., a Kitov Pharmaceuticals Holdings Ltd. (NASDAQ and TASE: KTOV) company focused on the development of small molecules to overcome cancer drug resistance, has been selected to be a part of the Israel Pavilion at the 2017 BIO International Convention, taking place June 18-22, 2017, at the San Diego Convention Center, San Diego, CA. The Israeli Pavilion is being sponsored by the Israel Innovation Authority (formerly known as Office of the Chief Scientist of the Ministry of Economy and Industry).

  • PR Newswire10 months ago

    Kitov Pharmaceuticals Files 6-K with Update on Israeli Securities Authority Investigation

    Kitov Pharmaceuticals (NASDAQ: KTOV, TASE: KTOV) is an innovative biopharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov's veteran team of healthcare professionals maintains a proven track record in streamlined end-to-end drug development and approval.

  • Business Wire11 months ago

    Deadline Alert: GPM Reminds Investors of the April 10 Deadline in the Class Action Lawsuit Against Kitov Pharmaceutical Holdings LTD

    Glancy Prongay & Murray LLP reminds investors of the April 10, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Kitov Pharmaceutical Holdings LTD American Depository Receipts pursuant and/or traceable to the Company’s initial public offering on or about November 20, 2015 and/or between November 20, 2015 and February 3, 2017, inclusive .

  • Accesswire11 months ago

    EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals Holdings LTD and Encourages Investors with Losses to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / April 4, 2017 / Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Kitov Pharmaceuticals Holdings LTD ("Kitov" or the "Company") ...

  • Business Wire11 months ago

    April 10 Deadline Alert: Law Offices of Howard G. Smith Reminds Kitov Pharmaceutical Holdings LTD Investors of Upcoming Lead Plaintiff Deadline

    Law Offices of Howard G. Smith reminds investors of the upcoming April 10, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Kitov Pharmaceutical Holdings LTD American Depository Receipts pursuant and/or traceable to the Company’s initial public offering on or about November 20, 2015 and/or between November 20, 2015 and February 3, 2017, inclusive ...

  • Accesswire11 months ago

    Blog Coverage Kitov Received a $2 Million Filing Waiver from FDA

    Upcoming AWS Coverage on Protalix BioTherapeutics Post-Earnings Results LONDON, UK / ACCESSWIRE / April 4, 2017 / Active Wall St. blog coverage looks at the headline from Kitov Pharmaceuticals Holdings ...

  • Accesswire11 months ago

    APPROACHING DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals Holdings LTD and Reminds Investors with Losses to Contact the Firm

    IRVINE, CA / ACCESSWIRE / April 3, 2017 / Khang & Khang LLP (the "Firm") announces a class action lawsuit against Kitov Pharmaceuticals Holdings Ltd ("Kitov" or the "Company") ...

  • PR Newswire11 months ago

    U.S. Food and Drug Administration Grants Kitov a Waiver for New Drug Application Filing Fee

    Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Kitov a waiver related to the $2,038,100 New Drug Application (NDA 210045) filing fee for KIT-302. J. Paul Waymack, M.D., Sc.D., Kitov's Chairman of the Board and Chief Medical Officer, commented, "We are pleased to receive this NDA fee waiver for KIT-302 and look forward to continuing to work with the FDA through the NDA submission and review process.

  • Accesswire11 months ago

    SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Kitov Pharmaceuticals Holdings LTD to Contact the Firm

    NEW YORK, NY / ACCESSWIRE / April 2, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Kitov Pharmaceuticals Holdings LTD ("Kitov" or the "Company") ...